Compound Semaglutide
US$ 24.22
glp 1 pen Needles, pens and pressure: The GLP-1 challenge New study shows popular GLP-1
Description
Abrupt discontinuation can cause rebound appetite and metabolic changes
In the Wegovy-pill clinical trial, 18% of people who received the medication discontinued the treatment, which was less than the 26% rate in the placebo group
It's very exciting, but I don't think we have definitive data in these conditions
This is what has caused some people to view it as not only the next-generation anti-obesity drug but also as one to follow
We will cover this in more detail in a full guide: 9
They are also urging patients not to take semaglutide in combination with other diabetes medications unless directed by their doctor
